Reviews/Artificial Sweeteners/Erythritol linked to cardiovascular events
Cardio · ANSW-CVD-02 · v2
The question is whether consuming erythritol is linked to heart attacks, strokes and heart-related deaths. In several independent groups of people, higher erythritol levels in the blood went together with more cardiovascular events and deaths [9][12][15]. But those studies measured erythritol circulating in the blood, and the body makes a large amount of its own erythritol, so high blood levels may reflect existing ill health rather than what a person ate [15]. The one trial that actually fed people erythritol found no effect on blood-vessel function, and it did not track real heart events [1], while a genetic analysis found no sign that erythritol causes coronary heart disease [10]. Because the strong signal is a blood marker rather than measured diet, the panel treated the intake-specific question as genuinely unresolved.
Three independent cohorts link higher circulating erythritol to incident cardiovascular events and to cardiovascular and overall mortality [9][12][15], and a small ingestion study showed that consuming erythritol raises plasma levels above thresholds tied to platelet reactivity and thrombosis in laboratory work [9]. In [12], serum erythritol was associated with cardiovascular disease mortality (HR = 1.86 [95% CI = 1.18-2.94]). In [9], adjusted hazard ratios for events in the two validation cohorts were 1.80 (1.18-2.77) and 2.21 (1.20-4.07). However, the only trial to feed erythritol directly [1] found no statistically significant effect on vascular function, and a Mendelian randomization analysis [10] found no supportive evidence that erythritol increases coronary artery disease. The contested point: The division is between the exposure the studies actually measured — circulating or serum erythritol, which the corpus flags as substantially endogenous [15] — and erythritol as something that is eaten. The biomarker signal is consistent across cohorts [9][12][15], but whether dietary intake drives events is contradicted by the one direct intake trial [1] and unsupported by genetic evidence [10].
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Artificial Sweeteners, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Exposure substitution: all epidemiological associations [9][12][15] are with circulating/serum erythritol, not measured dietary intake; the corpus itself notes much circulating erythritol is endogenously synthesised, so the 'intake' claim rests on an unproven chain and is open to reverse causation.
Confounding by cardiometabolic health: [15] shows top-tertile erythritol tracks diabetes, hypertension, hyperlipidaemia, higher BMI and lower eGFR, consistent with erythritol as a biomarker of poor cardiometabolic status rather than a causal intake effect.
Where it remains uncertain. The associations rest on circulating (largely endogenous) erythritol, while the only direct-intake trial was null on vascular function [1] and Mendelian randomization found no causal effect on coronary artery disease [10].
Aleatory
The intake demonstration in [9] rests on only 8 healthy volunteers, so chance variation dominates.
Epistemic
The corpus cannot partition how much circulating erythritol comes from synthesis versus intake [15][16], the quantity the claim depends on.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Only direct erythritol-intake RCT; null on a vascular surrogate, no CV-event endpoint.
Panel auditInternal validity: medium · scope of inference: Short-term effect of dietary erythritol on vascular function and metabolic surrogates in people with obesity.Key limitations: surrogate endpoints not events · small sample · 5-week duration
Primary observational association of circulating erythritol with incident MACE, confirmed in two validation cohorts (HR 1.80 and 2.21).
“erythritol ingestion in healthy volunteers (n = 8) induced marked and sustained (>2 d) increases in plasma erythritol levels well above thresholds associated with heightened platelet reactivity and thrombosis potential in in vitro and in vivo studies”
Panel auditInternal validity: medium · scope of inference: Circulating erythritol levels and incident MACE in patients undergoing cardiac risk assessment.Key limitations: circulating not dietary intake · residual confounding · observational association
Genetic-instrument analysis finding no causal effect of erythritol on coronary artery disease, weakening the intake-causes-events interpretation.
“Across instruments, we did not find supportive evidence that increased erythritol increases CAD (b = -0.033 ± 0.02, P = 0.14; b = 0.46 ± 0.37, P = 0.23)”
Panel auditInternal validity: medium · scope of inference: Causal effect of circulating erythritol on CAD and cardiometabolic traits in European-ancestry cohorts.Key limitations: genetically predicted not intake · instrument strength · CAD not all CV events
Mechanistic animal/pathway support for a prothrombotic effect of erythritol; indirect to human events.
“While erythritol exacerbated HFD-induced increased platelet aggregation, allulose treatment significantly reduced it”
Panel auditInternal validity: low · scope of inference: Effect of erythritol versus allulose on platelet aggregation pathways in mice and SCD gene expression.Key limitations: mechanistic surrogate not events · animal/in silico model · no reported statistics
4 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A robust circulating-biomarker signal exists, but the intake-specific claim is confounded, supported only indirectly, and contradicted by the one direct trial and the MR analysis, leaving it genuinely unresolved.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Measured intake against adjudicated events. Every association uses circulating erythritol, not quantified diet [9][12][15], so the intake claim is untested on real outcomes. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Prospective cohort quantifying dietary erythritol intake with adjudicated major adverse cardiovascular events.
Open question: Does measured dietary erythritol intake, as opposed to circulating levels, predict cardiovascular events? Why it is still open: All cohorts measured circulating or serum erythritol rather than intake [9][12][15].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19